Compare Snap Inc (SNAP) vs TG Therapeutics Inc (TGTX) Price & Performance

Snap Inc. (SNAP) trades at $5.43, down 0.73% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported a net loss of $460.49 million in 2025, but revenue grew to $5.93 billion, and recent quarters have shown earnings beats. Analyst consensus is a 'Hold' with a $7.02 price target, while legal challenges and insider sales add volatility.

Outlook remains cautious due to persistent losses and regulatory risks, but improving revenue and narrowing losses offer potential upside if execution improves. Key risks include youth-safety lawsuits and competitive pressures, while institutional buying and earnings momentum provide support for patient investors.

TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The stock shows strong profitability with a net income margin of 55.22% and ROE of 100.28%, though recent quarters have seen earnings misses. Revenue growth is robust, with 2026 guidance raised to $950 million for BRIUMVI, and buyout rumors have fueled positive sentiment.

The outlook for TGTX is positive driven by BRIUMVI's commercial success and pipeline catalysts, but risks include earnings volatility, high valuation multiples, and competitive pressures. Institutional accumulation supports upside, yet investors should weigh execution risks against growth potential.